Nausea and Vomiting, Aromatherapy, Essential Oil, Suportive Care
Conditions
Brief summary
The investigator wish to provide a blend of two essential oils with comparable antiemetic properties; Peppermint essential oil (Mentha x Piperita) and lemon tree essential oil (Citrus Limon). Dry inhalation of these essential oils is safe, but effectiveness has not been determined. Studies on the subject present a questionable methodology. This is why we are proposing this study to measure the effectiveness of this mixture of essential oils on chemo-induced nausea and vomiting. This study is a first step before a possible study to compare the effects of essential oils with those of a placebo.
Interventions
DRUGEssential oils
The patient will be invited to inhale the essential oils via the stick: * 4 times a day before each meal and snack. * if necessary when nausea appears, as many times as he deems necessary.
Sponsors
Centre Francois Baclesse
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Open, prospective, single-center phase 2 study
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients will be eligible if: * Aged over 18, * Presenting a solid tumor in the 1st line of chemotherapy administered by intravenous route; * Treated with adjuvant or neoadjuvant chemotherapy; * Affiliated with a social security scheme; * Able to understand the meaning of the questions asked; * Having given their written consent to participate in the study; * Whether or not treated with surgery and radiotherapy before entering the study
Exclusion criteria
Patients who: * Do not give their consent to participate; * Do not master the French language; * Are deprived of their liberty, under guardianship or curatorship; * Suffer from cognitive deficits or associated psychiatric disorders that could compromise their ability to participate in the study (eg: schizophrenia); * Are undergoing radiotherapy; * Must receive a combination of radio-chemotherapy; * Whose chemotherapy protocol is composed of several chemotherapy administrations per week during a course of treatment; * have been previously treated with chemotherapy; * Have an occlusive syndrome; * Have primary cancer of the central nervous system or brain metastases; * Have cancer of the Upper Aero Digestive Tract; * Simultaneously participate in a therapeutic clinical trial; * Have an intolerance to a component of essential oils; * Pregnant or breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of episodes of nausea and vomiting | 4 days after the first cycle of chemotherapy |
Secondary
| Measure | Time frame |
|---|---|
| Number of episodes of nausea and vomiting | 4 days after the third cycle |
| Anxiety with self-questionnaire HADS | 21 days after the third cycle |
Countries
France
Outcome results
None listed